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The dataset presented in this article complements the article
entitled “Myeloid cells contribute indirectly to VEGF expression
upon hypoxia via activation of Müller cells” (C. Nürnberg, N.
Kociok, C. Brockmann, T. Lischke, S. Crespo-Garcia, N. Reichhart, S.
Wolf, R. Baumgrass, S.A. Eming, S. Beer-Hammer, and A.M. Jous-
sen). This complementary dataset provides further insight into the
experimental validation of the VEGFfl/fl LysMCre (here named
VEGFmcko) knockout model used in the main article through
genomic and quantitative Real-Time PCR in various murine tissues
as well as additional flow cytometry data and immunohisto-
chemical stainings. By providing these data, we aim to enable
researcher to reproduce and critically analyze our data.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).vier Inc. This is an open access article under the CC BY-NC-ND license
/).
.exer.2017.10.011
heidelberg.de (C. Nürnberg).
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acquiredPCR processor (LightCycler 480, Roche, Basel Switzerland),
FACS (LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA)),
data analyzed with FlowJo software (version 9.8.1; Treestar, Ashland, OR, USA),
Microscope (Axio Imager.M2 microscope (Zeiss, Jena, Germany)ata format Analyzed
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factorsVEGF-Afl/fl LysMCretg/þ (here named VEGFmcko) and C57Bl/6J were used as
experimental animals. VEGF-Afl/fl LysMCreþ /þ (here named controls) were
used as controlsxperimental
featuresqPCR: RNA-isolation was conducted with the NucleoSpin RNA Mini Kit
(Machery Nagel, Düren, Germany) For reverse transcription of cDNA, the
“High-Capacity cDNA Reverse Transcription Kit” (Applied Biosystems, Darm-
stadt, Germany) was used.
FACS: Spleen, bone marrow and retina samples were mashed through cell
strainer (70 μm for spleen and bone marrow and 40 μm for the retina).
Afterwards, the cells were re-suspended in PBS, centrifuged and used for FACS
analysis.ata source
locationBerlin, Germanyata accessibility Data are with this article
elated research
articleChristina Nürnberg, Norbert Kociok, Claudia Brockmann, Timo Lischke, Sergio
Crespo-Garcia, Nadine Reichhart, Susanne Wolf, Ria Baumgrass, Sabine A.
Eming, Sandra Beer-Hammer, and Antonia M. Joussen. Myeloid cells contribute
indirectly to VEGF expression upon hypoxia via activation of other cell types
Müller cells. Exp. Eye Res. 2017.Value of the Data
These data give an overview of the relative Cre mRNA expression in the retina as well as the
genomic recombination efficiency in brain and bone marrow and the Cre and VEGF-A mRNA
expression in brain, bone marrow and lung as part of the validation of the VEGFfl/fl LysMCre (here
named VEGFmcko) knockout mouse model. These data are important for the use of the same knockout
mouse in other studies.
Flow cytometric data providing an overview of T memory cells, natural killer (NK) cells, and
natural killer-T (NKT) cells as percentage of CD45 positive cells in the retina of knockout and control
retinas under normoxic and hypoxic conditions are presented.
The presented pathological retinal features in the model of oxygen-induced retinopathy in clo-
dronate-liposome treated mice is of interest for similar studies.1. Data
Seven-day-old pups and the nursing dam were exposed to a 75% oxygen containing environment
for five days before replacement in normal housing conditions causing a neovascular stimulus via
relative hypoxia until further analysis on postnatal days 14 and 17. The oxygen box was opened daily
for a very short period to check on pups and mother.
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The experimental procedures are described in the related research article: Nürnberg et al. [1] (Table 1).
A more detailed description of some of the methods used in this article as followed Figs. 1-8:3. Material and methods
3.1. Mouse model of oxygen induced retinopathy
Oxygen Induced Retinopathy (OIR) was induced as described in the main text with few mod-
ifications (Fig. 1). The nursing dam as well as the offspring was kept under normal housing conditions
from day P0 to P7. On day P7 the animals were exposed to a 75% oxygen containing environment for
five days using a special oxygen chamber (Model THF3384, EHRET Labor- u. Pharmatechnik GmbH,
Emmendingen, Germany). In contrast to the original protocol [2], the oxygen chamber was opened
once daily for a few minutes to check on dam and pups. On P12 the mice were transferred back into
normal housing conditions until P14 or P17 for analysis. A surrogate dam was provided if the nursing
dam passed away – a very rare occurrence though. Room air controls were kept under normal
housing conditions at all times.Fig. 1. Oxygen-induced retinopathy mouse model.
Table 1
Antibodies used.
Antibody Concentration Source Catalogue Number
Rabbit-anti GFAP 1:250 DAKO Z0334
Mouse anti-Vimentin 1:50 Santa-Cruz sc-32322
Goat anti-rabbit IgG Cy3 1:200 Dianova 111–165-144
Rabbit anti-mouse IgG Alexa488 1:200 Invitrogen A11059
Rabbit anti-VEGF-A 1:100 Abcam ab46154
Donkey anti-rabbit AlexaFluor488 1:10.000 Invitrogen A-21206
Rabbit anti-CD11b 1:100 Novus Biologicals NB110-89474
Rat anti-mouse CD11b 1:200 Antibodies-online.com ABIN474860
Goat anti-rat Cy3 1:200 Dianova 112–165-003
AF488-conjugated Isolectin-IB4 1:200 Invitrogen l21411
FITC anti-mouse F4/80 clone BM8 1:100 Biolegend 123108
PerCP-Cy5.5 anti-mouse Ly6C clone HK1.4 1:200 Biolegend 128012
APC/Cy7 anti-mouse NK1.1 clone PK136 1:200 Biolegend 108724
PE anti-mouse CD45 clone 30-F11 1:200 BD Biosciences 553081
PE-Cy7 anti-mouse CD11b clone M1/70 1:200 BD Biosciences 561098
APC-Cy7 anti-mouse Ly6G clone 1A8 1:200 BD Biosciences 560600
AF405 anti-CD3 clone KT3 1:200 DRFZ Berlin, Germany none
Fig. 2. Validation of the VEGFfl/fl LysMCre mouse model in the retina. (A) Relative Cre mRNA expression levels in the retina.
Measurement of relative Cre mRNA expression levels by quantitative Real-Time PCR in VEGFmcko and control mice under
normoxic and hypoxic conditions (animal numbers per group are indicated in the figure on each bar) as an indirect indication
of the occurrence of recombination in the retina on P14 (VEGFmcko hypoxia 5.48×10−475.56×10−4; VEGFmcko normoxia
6.63×10−4710.06×10−4) and on P17 (VEGFmcko hypoxia 6.46×10−476.85×10−4; VEGFmcko normoxia 11.13×10−4718.58×10−4).
(Cre mRNA expression in the control tissues brain and bone marrow Fig. 3C, D). (B) Genomic recombination efficiency in
various murine tissues. Detection of the length of the VEGF-A gene in thyme (A), brain (B), spleen (C) and bone marrow (D) in
three mice per group of VEGFmcko (VEGFfl/fl Cretg/þ) and two types of control animals through genomic PCR analysis. DNA from
the bone marrow and spleen was isolated after magnetic cell sorting of CD11b positive cells. A 420 bp fragment in VEGFmcko
mice (VEGFfl/fl Cretg/þ) indicates the occurrence of recombination, a 1934 bp long fragment was found in the floxed and a 1866
bp long fragment in the wildtype control animals. (C) Screen for Pdebrd1 mutation. Genomic PCR screen for a Pdebrd1 mutation
causing postnatal photoreceptor degeneration in three VEGFmcko (VEGFfl/fl Cretg/þ) and three control animals (VEGFfl/fl Creþ /þ).
A 400 bp long fragment was proof of the presence of a wildtype allele and ruled out the presence of the mutation, which would
have been indicated by a 550 bp long band.
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isolation. All animals were re-genotyped after completion of the experiment by tail tip biopsy. For the
VEGF-A flox PCR the following primers were used: muVEGF419.F (5′-CCTGGCCCTCAAGTACACCTT-3′);
muVEGF567.R (5′-TCCGTACGACGCATTTCTAG-3′). In the presence of a loxP-1 site these primers generated a
168 bp long fragment, and an approximately 100 bp long band in the wildtype. Evidence of the LysMCre
transgene was shown using the following primers: IMR3066 (5′-CCCAGAAATGCCAGATTACG-3′); IMR3067
(5′-CTTGGGCTG CCAGAATTTCTC-3′); IMR3068 (5′-TTACAGTCGGCCAGGCTGAC-3′). Presence of the trans-
gene was indicated by a 700 bp long band and the presence of a wildtype allele by a 350 bp long band.3.2. Mouse organ dissection
Organs of mice were dissected for various reasons including genomic PCR, mRNA expression level
analysis, histological analysis and flow cytometry. All mice were first narcotized using a mixture of
10 mg/g bodyweight ketamine (Ketamine-Actavis®, Actavice Group PTC ehf., Hafnarfjördur, Island)
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vical dislocation, and the tail tip was cut off for the second confirmation of the genotype. Both the
femoral and the tibial bone were extracted from the leg, the bone marrow flushed out with a 20G
syringe needle (B. Braun, Melsungen, Germany) into the tube with PBS, and centrifuged at 1400 rpm
for five minutes. The thorax was cut open and thyme, spleen as well as the lungs were dissected and
cleaned from blood as best as possible. The eyes were enucleated and dissected under microscopic
control. Cornea and lens were removed and the retina carefully dissected out of the eyecup removing
vitreous body and RPE cells as best as possible. Finally, the skull was cut open, the brain extracted and
cut into halves.
Fig. 3. Primer specificity analysis in the retina and cell culture Cre and VEGF-A mRNA expression analysis in relevant tissues and cells.
(A) Left panel: Primer specificity in the retina was monitored by separation of the amplification product in the retina of VEGFmcko and
control mice under normoxic und hypoxic conditions through a 2% agarose gel. The β-Actin primers amplified a 110 bp long product,
the VEGF-A primers 201 bp product and the Cre primers a 195 bp long product. Right panel: Primer specificity in humanMIO-M1 cells
was monitored by separation of the amplification products through a 2% agarose gel. β-Actin primers amplified a 206 bp long product
and the VEGF-A primers a 76 bp product. (B) After separation through an agarose gel, primer specificity was further verified by
purification and subsequent sequencing of the amplification product. The graph shows the transcript sequence for the amplification
product for each primer pair (β-Actin, VEGF-A, Cre). (C) Relative Cre mRNA expression levels in the brain. Measurement of relative Cre
mRNA expression levels of VEGFmcko and control mice on P14 and P17 under normoxic and hypoxic conditions in the brain (animal
numbers per group are indicated in the figure on each bar) (P14: control normoxia 2.18×10−776.53×10−7, VEGFmcko normoxia
7.76×10−579.83×10−5, control hypoxia 070, VEGFmcko hypoxia 070; P17: control normoxia 2.07×10−671.07×10−6, VEGFmcko nor-
moxia 0.003870.0078, control hypoxia 1.52×10−672.91×10−6, VEGFmcko hypoxia 0.0002470.00021). (D) Relative Cre mRNA
expression levels in the bone marrow. Measurement of relative Cre mRNA expression levels of VEGFmcko and control mice on P14 and
P17 under normoxic and hypoxic conditions in the bone marrow (animal numbers per group are indicated in the figure on each bar)
(P14: control normoxia 7.89×10−570.00017, VEGFmcko normoxia 0.01270.0089, control hypoxia 070, VEGFmcko hypoxia
0.0170.0028; P17: control normoxia 2.47×10−673.95×10−6, VEGFmcko normoxia 0.01470.0071, control hypoxia 0.0001170.00023,
VEGFmcko hypoxia 0.00770.0016). (E) Relative VEGF-A mRNA expression levels in the brain (microglia cells). Measurement of relative
VEGF-A mRNA expression levels of VEGFmcko and control mice on P14 and P17 under normoxic and hypoxic conditions in the brain
(animal numbers per group are indicated in the figure on each bar) (P14 VEGFmcko normoxia 0.01570.015; P17 VEGFmcko normoxia
0.08670.049). (F) Relative VEGF-A mRNA expression levels in the bone marrow. Measurement of relative VEGF-A mRNA expression
levels of VEGFmcko and control mice on P14 and P17 under normoxic and hypoxic conditions in the bone marrow (animal numbers per
group are indicated in the figure on each bar) (P14: control normoxia 0.009370.0037, VEGFmcko normoxia 0.005670.0018, control
hypoxia 0.01370.0046, VEGFmcko hypoxia 0.008270.004; P17: control normoxia 0.004870.0013, VEGFmcko normoxia
0.004670.0007, control hypoxia 0.008370.0069, VEGFmcko hypoxia 0.003470.0006). (G) Relative VEGF-AmRNA expression levels in
the lungs. Measurement of relative VEGF-AmRNA expression levels of VEGFmcko and control mice on P14 and P17 under normoxic and
hypoxic conditions in the bone marrow (animal numbers per group are indicated in the figure on each bar). The lungs served as
positive control organs for VEGF-A mRNA analysis. (P14 control normoxia 0.2170.072, VEGFmcko normoxia 0.18370.068,) control
hypoxia 0.14970.031, VEGFmcko hypoxia 0.14870.017; P17 control normoxia 0.24470.031, VEGFmcko normoxia 0.22170.067, control
hypoxia 0.2370.037).
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For purification of total genomic DNA from different mouse tissues, the DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany) was used and the manufacturer's instructions were followed.
3.4. mRNA expression levels
For reverse transcription of cDNA, the “High-Capacity cDNA Reverse Transcription Kit” (Applied
Biosystems, Darmstadt, Germany) was used and the manufacturer's instructions were followed. In
this experimental setup, β-Actin was chosen as the housekeeping gene for control since oxygen
treatment influences the expression levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
in vitro [3]. Transcripts of interest were cDNAs encoding Cre and VEGF-A in the retina, bone marrow
or brain. SensiFAST SYBR (BIOLINE, Luckenwalde, Germany) was used for quantitative Real-Time PCR
purposes, and the manufacturer's instructions were followed. The following primers were used:
VEGF-A fwd (5′-CAGCTATTG CCGTCCGATTGA GA-3′) and VEGF-A rev (5′-TGC TGG CTT TGG TGA GGT
TTG AT-3′) amplifying a 201 bp long product; Cre fwd (5′-GATTTCGACCAGGTTCGTTC-3′) and Cre rev
(5′-GCT AACCAGCGTTTTCGTTC-3′); β-Actin fwd (5′-AAGGCCAACCGTGAAAAGAT-3′) and β-Actin rev
(5′-GTGGTACGACCAGAGGCATAC). The samples were analyzed in a LightCycler 480 and calculations
were performed using the LightCycler software (Roche, Basel, Switzerland). All samples were run in
triplicates and the melting curve of each product was monitored and probes with unspecific melting
curves were excluded from the analysis. In order to verify the specificity of the primers that were
Fig. 3. (continued)
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the agarose using QIAquick Gel Extraction Kit (Qiagen) and the manufacturer's instructions were
followed before sequencing. Due to a very high amount of mRNA yield, the beta-Actin primers bound
at a second binding site within the beta-Actin sequence, causing double peak melting curve.
Sequencing of both peaks revealed that both products were beta-Actin products. Also the other
products were primer specific.
Fig. 4. Flow cytometry of T memory cells, natural killer (NK) cells, and natural killer-T (NKT) cells as percentage of CD45
positive cells in the retina. (A) T memory cells as percentage of CD45 positive cells (% Ly6CþCD3þ of CD45þ cells): P14 hypoxia:
VEGFmcko n¼8; 2.071.14%; control n¼9; 1.5670.64%; P17 hypoxia: VEGFmcko n¼5; 1.2370.78%; control n¼7; 1.1670.38%.
P14 normoxia: VEGFmcko n¼15; 0.5570.48%; control n¼6; 0.4170.41%; P17 normoxia: VEGFmcko n¼10; 0.270.08%; control
n¼7; 0.1370.07%. (B) NK cells as percentage of CD45 positive cells (% NK1.1þCD3- of CD45þ cells): P14 hypoxia: VEGFmcko
n¼6; 2.3672.61%; control n¼7; 0.871.71%. P14 normoxia VEGFmcko n¼12; 0.3271.67%; control n¼6; 0.2670.27%. P17
hypoxia VEGFmcko n¼5; 0.2470.11%; control n¼7; 0.4770.17%. P17 normoxia VEGFmcko n¼10; 0.1270.05%; control n¼7;
0.1270.07%. (C) NKT cells as percentage of CD45 positive cells (% NK1.1þCD3þ of CD45þ cells): P14 hypoxia: VEGFmcko n¼8;
13.91711.24%; control n¼9; 13.0274.92%. P17 hypoxia: VEGFmcko n¼5; 5.1171.35%; control n¼7; 4.5371.47%. P14 nor-
moxia: VEGFmcko n¼15; 6.774.43%; control n¼8; 4.8373.93%. P17 normoxia: VEGFmcko n¼10; 0.3670.23%; control n¼7;
0.1270.07%.
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Fig. 5. Histochemistry of CD11b positive cells in spleen sections. Representative staining of CD11b positive cells in spleens of
control mice kept under hypoxic conditions. Clodronate injection (right) led to a depletion of CD11b positive cells whereas
sections of PBS injected controls (left) still showed a considerable amount of CD11b positive cells (dark staining).
Fig. 6. Presence of mononuclear phagocytes (MPs) in close proximity to blood vessels. Representative images for mononuclear
phagocytes (CD11b in red) and vessels (AF488-Isolectin-IB4 in green) of retinal flatmount preparations on P14 and P17 under
hypoxic conditions in control mice.
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Fig. 7. Water control for vimentin and GFAP stainings for Müller cell activation. Representative images of water controls for
vimentin (rabbit anti mouse-IgG-Alexa488 as secondary antibody) and GFAP (goat anti rabbit-IgG-Cy3 a secondary antibody)
staining of Müller cells on P17 under hypoxic conditions in VEGFmcko mice. The primary antibodies were omitted. Nuclei are co-
stained with DAPI. Primary antibodies used: rabbit anti-GFAP (DAKO, Glostrup, Denmark) and monoclonal mouse anti-
Vimentin antibody (Santa Cruz, Dallas, Texas, USA).
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Fig. 8. Assessment of pathological retinal features in OIR in clodronate-liposome treated mice on P17. (A) Representative
Isolectin IB4 staining of endothelial cells on retinal whole flatmounts. Images taken on P17 in control mice under hypoxic
conditions in clodronate-liposome treated mice and the respective PBS-liposome treated controls. (B) Relative avascular area.
Analysis of the avascular area relative to the total area of the whole flatmount on Isolectin-IB4 stained retinal flatmounts. Each
symbol represents one individual mouse and red data points in every group indicate the matching images shown in (A).
Clodronate n¼7, 6.1775.86%; PBS n¼6, 9.1473.32%. (C) Relative tuft area. Analysis of the tuft area relative to the total area of
the whole flatmount on Isolectin-IB4 stained retinal flatmounts. Each symbol represents one individual mouse and red data
points in every group indicate the matching images shown in (A). Clodronate n¼7, 1.7971.56%; PBS n¼5, 2.4271.68%.
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